Lanluma

Lanluma is an injectable poly-L-lactic acid (PLLA) implant commercialized by Sinclair. Its product identity includes two notably different vial strengths—Lanluma V and Lanluma X—and a prominent face-and-body clinical context. It should not inherit Sculptra’s formulation or preparation instructions simply because both products use PLLA.

Quick reference

Field	Lanluma
Material	Poly-L-lactic acid
Presentations	Lanluma V: 210 mg PLLA; Lanluma X: 630 mg PLLA
Product form	Powder in a vial requiring preparation
Preparation	Presentation- and market-specific; use the current IFU
Immediate correction	Reconstitution fluid is not the same as the later tissue response
Commercial company	Sinclair
Main comparison	Sculptra

The V and X strengths are identified in a Sinclair/Lanluma surgeon leaflet: one 210 mg vial for Lanluma V and one 630 mg vial for Lanluma X (Lanluma surgeon leaflet 🔗).

Product family and presentation

The difference between 210 mg and 630 mg is large enough that Lanluma should not be treated as one undifferentiated vial. A useful product record should identify:

V or X presentation
vial strength
intended area and objective
preparation volume
final concentration
session context
region and IFU version

Lanluma V and Lanluma X belong on one brand page while their presentation differences remain visible. They should split into separate pages only if future regional labels or evidence require independently substantial entries.

Preparation belongs to the exact presentation

Lanluma requires preparation before use, but public-facing brand material is not a substitute for the current IFU. The final concentration depends on both vial strength and preparation volume.

Do not:

apply Sculptra’s 5–8 mL reconstitution range to Lanluma
apply one Lanluma presentation’s preparation to the other
describe a face protocol as a body protocol
use a commercial training slide as proof of approved use
omit final concentration when comparing preparations

Preparation claims should identify whether they come from an IFU, formal manufacturer training, consensus, or a clinical study.

Face and body context

Sinclair presents Lanluma as a PLLA injectable for facial and body treatment contexts (Sinclair Lanluma 🔗). The same page describes the regulated indication as increasing the volume of depressed areas, particularly correction of skin depressions.

Those two statements are not identical. Public commercial discussion of neck, décolleté, abdomen, arms, thighs, or buttocks should not automatically be written as one region-wide approved indication.

Clinical evidence: useful but bounded

A prospective, open-label, uncontrolled post-market study reported nine-month outcomes for 70 participants and 99 Lanluma treatment sessions involving the neck, upper arm, hand, thigh, and décolleté. Lumps and nodules were the most frequently reported treatment-related adverse events; no event was serious, severe, or fatal in that interim analysis (Journal of Cosmetic Dermatology 🔗).

The study is useful because it is product-specific and reports body-area experience. Its limits remain important:

no control group
open-label design
interim nine-month analysis
modest sample size
treatment protocols tied to the study
results not transferable to every anatomy or preparation

Do not convert satisfaction ratings or the absence of severe events in this cohort into a universal superiority or safety claim.

Immediate appearance and delayed response

Like other reconstituted PLLA products, Lanluma can create early fluid-related change that is not the same as the later tissue response. Consultation and outcome reporting should separate:

the immediate post-injection appearance
absorption of reconstitution fluid
gradual tissue change
maintenance or additional-session decisions

The timetable should come from the exact product information or study being discussed.

Company and manufacturing roles

Role	Supported relationship
Brand commercialization	Sinclair
Product presentations	Lanluma V and Lanluma X
Legal or physical manufacturer	Verify from the exact regional IFU
Approval holder	Market-specific
Distributor	Market-specific

Public Lanluma pages can display different regional manufacturing or distribution statements. Injectable Index therefore does not flatten Sinclair’s commercial role into a universal physical-manufacturer claim.

The Sinclair company page separates portfolio ownership and commercialization from product-level manufacturing.

Safety and limitations

Lanluma safety interpretation should preserve:

presentation and final concentration
treated anatomy
placement and distribution
timing of a lump or nodule
inflammatory signs
infection assessment
study or label context

The body study distinguished a non-inflamed palpable lump from an inflamed, potentially red or painful nodule. That terminology is useful, but it should not replace clinical evaluation of an individual event.

Nearby reference pages

Face vs body prevents facial assumptions from becoming a body protocol.
Immediate vs delayed effects distinguishes reconstitution-fluid appearance from later assessment.
European Union regulation records the current Sinclair CE and intended-use evidence without extending it to other markets.
Clinical practice framework connects product selection to follow-up and escalation.
Documentation and follow-up keeps exact presentation, anatomy, and later findings traceable.
Sculptra vs Lanluma compares presentation, documentation, and use context.
Ready-to-use vs reconstituted maps the additional controls required before injection.
PLLA explains the material-level context.
Sculptra provides a product-specific PLLA comparison.
AestheFill shows how a PDLLA formulation differs from PLLA products.
Collagen Stimulators maps the wider product and company graph.